X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs CADILA HEALTHCARE - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA CADILA HEALTHCARE CIPLA/
CADILA HEALTHCARE
 
P/E (TTM) x 43.5 34.9 124.8% View Chart
P/BV x 3.6 9.0 39.9% View Chart
Dividend Yield % 0.4 0.7 52.5%  

Financials

 CIPLA   CADILA HEALTHCARE
EQUITY SHARE DATA
    CIPLA
Mar-17
CADILA HEALTHCARE
Mar-16
CIPLA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs622454 136.9%   
Low Rs458305 150.5%   
Sales per share (Unadj.) Rs181.996.1 189.2%  
Earnings per share (Unadj.) Rs12.914.9 86.5%  
Cash flow per share (Unadj.) Rs29.317.8 164.5%  
Dividends per share (Unadj.) Rs2.003.20 62.5%  
Dividend yield (eoy) %0.40.8 43.9%  
Book value per share (Unadj.) Rs155.752.3 297.8%  
Shares outstanding (eoy) m804.511,023.74 78.6%   
Bonus/Rights/Conversions ESOPFV5:1-  
Price / Sales ratio x3.03.9 75.2%   
Avg P/E ratio x42.025.5 164.5%  
P/CF ratio (eoy) x18.421.3 86.6%  
Price / Book Value ratio x3.57.3 47.8%  
Dividend payout %15.521.5 72.2%   
Avg Mkt Cap Rs m434,516388,458 111.9%   
No. of employees `00023.015.4 149.2%   
Total wages/salary Rs m26,33813,317 197.8%   
Avg. sales/employee Rs Th6,349.16,371.1 99.7%   
Avg. wages/employee Rs Th1,143.0862.4 132.5%   
Avg. net profit/employee Rs Th449.3986.1 45.6%   
INCOME DATA
Net Sales Rs m146,30298,376 148.7%  
Other income Rs m2,287941 243.0%   
Total revenues Rs m148,58999,317 149.6%   
Gross profit Rs m24,75823,829 103.9%  
Depreciation Rs m13,2293,022 437.8%   
Interest Rs m1,594486 327.9%   
Profit before tax Rs m12,22221,262 57.5%   
Minority Interest Rs m0-300 0.0%   
Prior Period Items Rs m-705 -1,398.0%   
Extraordinary Inc (Exp) Rs m0-25 0.0%   
Tax Rs m1,7985,716 31.4%   
Profit after tax Rs m10,35415,226 68.0%  
Gross profit margin %16.924.2 69.9%  
Effective tax rate %14.726.9 54.7%   
Net profit margin %7.115.5 45.7%  
BALANCE SHEET DATA
Current assets Rs m87,37044,376 196.9%   
Current liabilities Rs m33,08134,071 97.1%   
Net working cap to sales %37.110.5 354.2%  
Current ratio x2.61.3 202.8%  
Inventory Days Days8754 161.5%  
Debtors Days Days6262 99.9%  
Net fixed assets Rs m111,56747,896 232.9%   
Share capital Rs m1,6091,024 157.1%   
"Free" reserves Rs m123,64548,746 253.7%   
Net worth Rs m125,25453,519 234.0%   
Long term debt Rs m36,4548,964 406.7%   
Total assets Rs m209,532100,163 209.2%  
Interest coverage x8.744.7 19.4%   
Debt to equity ratio x0.30.2 173.8%  
Sales to assets ratio x0.71.0 71.1%   
Return on assets %5.715.7 36.4%  
Return on equity %8.328.4 29.1%  
Return on capital %8.534.3 24.8%  
Exports to sales %34.245.3 75.6%   
Imports to sales %8.35.9 140.6%   
Exports (fob) Rs m50,05044,537 112.4%   
Imports (cif) Rs m12,2035,838 209.0%   
Fx inflow Rs m51,06644,881 113.8%   
Fx outflow Rs m17,6789,069 194.9%   
Net fx Rs m33,38835,812 93.2%   
CASH FLOW
From Operations Rs m23,82419,938 119.5%  
From Investments Rs m-13,127-9,039 145.2%  
From Financial Activity Rs m-13,239-9,527 139.0%  
Net Cashflow Rs m-2,4781,372 -180.6%  

Share Holding

Indian Promoters % 16.0 74.8 21.4%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.3 147.0%  
FIIs % 23.7 5.9 401.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 11.0 238.2%  
Shareholders   161,166 44,069 365.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 21, 2017 03:37 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS